Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Visualization of Blood Glucose Fluctuations Using Continuous Glucose Monitoring in Patients Undergoing Hemodialysis.

Mori K, Emoto M, Abe M, Inaba M.

J Diabetes Sci Technol. 2019 Mar;13(2):413-414. doi: 10.1177/1932296818818429. Epub 2018 Dec 23. No abstract available.

PMID:
30580579
2.

Efficacy and safety of teneligliptin in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring.

Yajima T, Yajima K, Hayashi M, Takahashi H, Yasuda K.

Diabetes Res Clin Pract. 2016 Dec;122:78-83. doi: 10.1016/j.diabres.2016.10.016. Epub 2016 Oct 21.

PMID:
27810689
3.

Improved glycemic control with teneligliptin in patients with type 2 diabetes mellitus on hemodialysis: Evaluation by continuous glucose monitoring.

Wada N, Mori K, Nakagawa C, Sawa J, Kumeda Y, Shoji T, Emoto M, Inaba M.

J Diabetes Complications. 2015 Nov-Dec;29(8):1310-3. doi: 10.1016/j.jdiacomp.2015.07.002. Epub 2015 Jul 3.

PMID:
26298521
4.

A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis.

Homma K, Yoshizawa J, Shiina Y, Ozawa H, Igarashi M, Matsuoka T, Sasaki J, Yoshizawa M, Homma Y.

Drugs R D. 2017 Sep;17(3):397-402. doi: 10.1007/s40268-017-0189-5.

5.

Blood glucose fluctuations in hemodialysis patients with end stage diabetic nephropathy.

Jin YP, Su XF, Yin GP, Xu XH, Lou JZ, Chen JJ, Zhou Y, Lan J, Jiang B, Li Z, Lee KO, Ye L, Ma JH.

J Diabetes Complications. 2015 Apr;29(3):395-9. doi: 10.1016/j.jdiacomp.2014.12.015. Epub 2014 Dec 31.

PMID:
25681043
6.

Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study.

Tanaka K, Okada Y, Mori H, Inada Y, Suzuka K, Uriu K, Tanaka Y.

Diabetol Int. 2016 Mar 9;7(4):368-374. doi: 10.1007/s13340-016-0258-y. eCollection 2016 Dec.

7.

Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.

Tanaka S, Suzuki K, Aoki C, Niitani M, Kato K, Tomotsune T, Aso Y.

Diabetes Technol Ther. 2014 Dec;16(12):840-5. doi: 10.1089/dia.2014.0095. Epub 2014 Aug 21.

8.

Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes.

Otsuki H, Kosaka T, Nakamura K, Shimomura F, Kuwahara Y, Tsukamoto T.

Int Urol Nephrol. 2014 Feb;46(2):427-32. doi: 10.1007/s11255-013-0552-6. Epub 2013 Sep 8.

PMID:
24014134
9.

Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.

Tsuchimochi W, Ueno H, Yamashita E, Tsubouchi C, Sakoda H, Nakamura S, Nakazato M.

Endocr J. 2015;62(1):13-20. doi: 10.1507/endocrj.EJ14-0393. Epub 2014 Sep 25.

10.

The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis.

Terawaki Y, Nomiyama T, Akehi Y, Takenoshita H, Nagaishi R, Tsutsumi Y, Murase K, Nagasako H, Hamanoue N, Sugimoto K, Takada A, Ito K, Abe Y, Sasatomi Y, Ogahara S, Nakashima H, Saito T, Yanase T.

Diabetol Metab Syndr. 2013 Feb 28;5(1):10. doi: 10.1186/1758-5996-5-10.

11.

Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study.

Osonoi T, Saito M, Tamasawa A, Ishida H, Tsujino D, Nishimura R, Utsunomiya K.

PLoS One. 2014 Dec 19;9(12):e113468. doi: 10.1371/journal.pone.0113468. eCollection 2014.

12.

Teneligliptin : expectations for its pleiotropic action.

Morishita R, Nakagami H.

Expert Opin Pharmacother. 2015 Feb;16(3):417-26. doi: 10.1517/14656566.2015.1000301. Review.

PMID:
25597385
13.

Teneligliptin in Management of Diabetic Kidney Disease: A Review of Place in Therapy.

Abubaker M, Mishra P, Swami OC.

J Clin Diagn Res. 2017 Jan;11(1):OE05-OE09. doi: 10.7860/JCDR/2017/25060.9228. Epub 2017 Jan 1. Review.

14.

The strong relation between post-hemodialysis blood methylglyoxal levels and post-hemodialysis blood glucose concentration rise.

Senda M, Ogawa S, Nako K, Okamura M, Sakamoto T, Ito S.

Clin Exp Nephrol. 2015 Jun;19(3):527-33. doi: 10.1007/s10157-014-1018-6. Epub 2014 Aug 20.

PMID:
25139482
15.

Inter-day glycemic variability assessed by continuous glucose monitoring in insulin-treated type 2 diabetes patients on hemodialysis.

Mirani M, Berra C, Finazzi S, Calvetta A, Radaelli MG, Favareto F, Graziani G, Badalamenti S.

Diabetes Technol Ther. 2010 Oct;12(10):749-53. doi: 10.1089/dia.2010.0052.

PMID:
20809678
17.
18.

Continuous Blood Glucose Monitoring Reveals Enormous Circadian Variations in Pregnant Diabetic Rats.

Golic M, Kräker K, Fischer C, Alenina N, Haase N, Herse F, Schütte T, Henrich W, Müller DN, Busjahn A, Bader M, Dechend R.

Front Endocrinol (Lausanne). 2018 May 29;9:271. doi: 10.3389/fendo.2018.00271. eCollection 2018.

19.

Hypoglycemic Coma in a Hemodialysis Patient Receiving Blood Glucose-Lowering Therapy With the Single Agent Teneligliptin.

Minezumi T, Takeda SI, Igarashi Y, Sato K, Murakami Y, Nagata D.

Clin Med Insights Case Rep. 2018 Mar 20;11:1179547618763358. doi: 10.1177/1179547618763358. eCollection 2018.

20.

Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes.

Kazempour-Ardebili S, Lecamwasam VL, Dassanyake T, Frankel AH, Tam FW, Dornhorst A, Frost G, Turner JJ.

Diabetes Care. 2009 Jul;32(7):1137-42. doi: 10.2337/dc08-1688. Epub 2009 Feb 5.

Supplemental Content

Support Center